0 out of results
The Uncommon Conversations in Drug Development LIVE series, hosted by the scientific and medical experts at Worldwide Clinical Trials, is more than your average networking event. Designed with emerging to midsized biopharma and pharma in mind, it’s an uncommon environment for our peers to collaborate, meet like-minded execs, and gain introductions to those who have successfully faced the same challenges.
START AT THE FINISH LINE: Mitigating Risk & Creating Value by Aligning Drug Development & Commercialization
Players in the drug development field experience increased pressure to solve many conflicting problems at once. How can you bring innovative and affordable drugs to key decision points in the R&D process while also balancing risk and value for multiple stakeholders?
The answer: Start with the end.
WHEN: 02 May 2019 | 4:00 PM – 6:30 PM
UNCOMMON VENUE: Nimb Hotel -Gemyse | Copenhagen, Denmark
AGENDA: 1-Hour Moderated Panel, 30-Minute Q&A, & 1-Hour Cocktail Reception
WHO SHOULD ATTEND
Founders, clinical and operations leaders and their teams seeking opportunities to mix it up and gain insight into the inside track…the know-how to avoid pitfalls, advice from their peers that have made mistakes, learned from them and then succeeded.
MEET THE PANELISTS
ANNE MARIE CONWAY BSN, MHA
Clinical Head of Biologics,
PTC Therapeutics, Inc.
JASON MEYENBURG M.B.A.
Chief Commercial Officer,
Orchard Therapeutics
MICHAEL MURPHY, M.D., Ph.D.
Chief Medical and
Scientific Officer,
Worldwide Clinical Trials
JEFF TROTTER M.B.A.
Senior Vice President of Worldwide Evidence,
Worldwide Clinical Trials
RESERVE YOUR SEAT
Your form has been successfully submitted! Thank you for your interest in Worldwide Clinical Trials. We will respond to your inquiry as soon as possible.
ABOUT WORLDWIDE CLINICAL TRIALS
Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services.
With infrastructure and talent spanning 60+ countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit www.worldwide.com.